NASDAQ:BHVN

Biohaven (BHVN) Stock Plunges on FDA Setback – Will Its Biotech Pipeline Fuel a Comeback?

Biohaven Ltd. shares plunged about 40% on Nov. 5, 2025, after the FDA rejected its lead drug VYGLXIA for spinocerebellar ataxia, citing trial design and data issues. The company will cut R&D spending by 60% and halt non-priority programs. Analysts downgraded the stock, which now trades near $8–9, down over 70% year-over-year. Biohaven reported a $198 million net loss in Q2 with $408 million in cash.

5 November 2025

NASDAQ:BHVN·Pharmaceuticals

Miracle Cure, Mega-Deals & Vaccine Drama: Global Biotech & Health Roundup (Aug 13–14, 2025)

The FDA approved Insmed’s brensocatib as the first therapy for non-cystic fibrosis bronchiectasis, following positive results in a 1,700-patient trial. Novartis reported Phase 3 successes for ianalumab in Sjögren’s syndrome and immune thrombocytopenia. In China, RemeGen’s telitacicept met its main goal in a Phase 3 Sjögren’s trial. Response Pharmaceuticals’ RDX-002 showed weight-loss maintenance in post-GLP-1 patients.

14 August 2025

NASDAQ:BHVN·NASDAQ:INSM·NYSE:NVS·Stock Market

Nvidia AI Stock Shows Potential for Generational Wealth in Expanding Market
March 20, 2026, 4:08 AM EDT. Nvidia, a leader in artificial intelligence (AI) chips, ended fiscal 2026 with $216 billion in revenue, up 65% year-over-year. The company expects $78 billion in revenue for the next quarter, marking a 77% increase. Nvidia dominates the AI chip market with a 90% share, in a sector projected to grow from $500 billion in 2026 to $1 trillion by 2030. Growth in AI-powered physical applications-robots, drones, autonomous vehicles-added $6 billion in revenue. Analysts see Nvidia's strong positioning in the rapidly expanding AI market as a driver for sustained growth and potential generational wealth for investors.